Prospective analysis after coronary-artery bypass grafting: Platelet GP IIIa polymorphism (HPA-1b/Pl(A2)) is a risk factor for bypass occlusion, myocardial infarction, and death

Thrombosis and Haemostasis

Volumn 83, Issue 3, 2000, Pages 404-407

  Zotz, Rainer B ^a,b   Klein, Michael ^a   Dauben, Hans Peter ^a   Moser, Christiane ^a   Gams, Emmeran ^a   Scharf, Rüdiger E ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Coronary artery bypass grafting; Glycoprotein IIb IIIa; Human platelet antigen 1 (HPA 1); Inherited risk factor

Indexed keywords

CHOLESTEROL; GLYCOPROTEIN IIIA; THROMBOCYTE ANTIGEN; TRIACYLGLYCEROL;

AGE; ARTERY OCCLUSION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; DIABETES MELLITUS; FEMALE; GENDER; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SAPHENOUS VEIN GRAFT; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034018291     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613827     Document Type: Article

References (30)

1. Fuster V. Prevention of atherosclerosis in coronary-artery bypass grafts. N Engl J Med 1997; 336: 212-3.
2. Pearson T, Rappaport E, Criqui M, Furberg C, Fuster V, Hiratzka L, Little W, Ockene I, Williams G. Optimal risk factor management in the patient after coronary revascularization. Circulation 1994; 90: 3125-33.
3. Lie JT, Lawrie GM, Morris GC Jr. Aortocoronary bypass saphenous vein graft atherosclerosis: anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months postoperatively. Am J Cardiol 1977; 40: 906-14.
4. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts: morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986; 6: 594-600.
5. Palac RT, Meadows WR, Hwang MH, Loeb HS, Pifarre R, Gunnar RM. Risk factors related to progressive narrowing in aortocoronary vein grafts studied 1 and 5 years after surgery. Circulation 1982; 66 (Suppl 1): 1-40-4.
6. Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P, Wacholder S, Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery, surgery. N Engl J Med 1984; 311: 1329-32.
7. Campeau L, Knatterud G, Domanski M, Hunninghake D, White CW, Geller NL, Rosenberg Y. The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts. N Engl J Med 1997; 336: 153-62.
8. Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type I: a model of deep vessel injury: influence of blood rheology, von Willebrand factor, and blood coagulation. Circulation 1988; 78: 1432-42.
9. Badimon L, Badimon JJ. Mechanism of arterial thrombosis in nonparallel streamlines: platelet thrombi grow at the apex of stenotic severely injured vessel wall: experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.
10. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Wenig D, Shah PK, Badimon L. Characterization of relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1564-9.
11. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissue: implication for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97.
12. Serneri GGN, Gensini GF, Poggesi L, Modesti PA, Rostagno C, Boddi M, Gori AM, Martini F, Ieri A, Margheri M, Abbate R. The role of dual thromboxane A2 inhibitor: importance of activated monocytes. Coronary Art Dis 1994; 5: 137-45.
13. Henderson WG, Goldman S, Copeland JG, Moritz TE, Harker LA. Anti-platelet or anticoagulant therapy after coronary artery bypass surgery: a meta-analysis of clinical trials. Ann Intern Med 1989; 111: 743-50.
14. Fremes SE, Levington C, Naylor CD, Chen E, Christakis GT, Goldman BS. Optimal antithrombotic therapy following aortocoronary bypass: a metaanalysis. Eur J Cardiothorac Surg 1993; 7: 169-80.
15. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992; 80: 1386-404.
16. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotcin receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
17. Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet PIA polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96: 1424-31.
18. A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998; 79: 731-5.
19. Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PLA polymorphism and myocardial infarction. (Letter) N Engl J Med 1996; 335: 1071-2.
20. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
21. Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996; 348: 1309-10.
22. A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost 1997; 77: 1179-81.
23. Klein M, Dauben HP, Schulte HD, Gams E. Centrifugal pumping during routine open heart surgery improves clinical outcome. Artif Organs 1998; 22: 326-36.
24. Zotz RB, Giers G, Maruhn-Debowski B, Scharf RE. Genetic typing of human platelet antigen 1 (HPA-1) by oligonucleotide ligation assay in a specific and reliable semi-automated system. Brit J Haematol 1997; 96: 198-203.
25. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988; 78 (Suppl II): I-140-3.
26. Komiyama N, Nakanishi S, Nishiyama S, Seki A. Intravascular imaging of serial changes of disease in saphenous vein grafts after coronary artery bypass grafting. Am Heart J 1996; 132: 30-40.
27. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50, 310-8.
28. Chesebro JH, Webster MWI, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ. Antithrombotic therapy and progression of coronary artery disease: anti-platelet versus antithrombins. Circulation 1992; 86 (Suppl III): III-100-10.
29. Goldman S, Copeland J, Moritz T, Henderson, Zadina K, Ovitt T, Kern KB, Sehti G, Sharma GVRK, Khuri S, Richards K, Grover F, Morrison D, Whitman G, Chesler E, Sako Y, Pacold I, Montoya A, DeMots H, Floten S, Doherty J, Read R, Scott S, Spooner T, Masud Z, Haakenson C, Kim T, Harker LA. Long-term graft patency (3 years) after coronary artery surgery: effects of aspirin: results of a VA cooperative study. Circulation 1994; 89: 1138-43.
30. A2). Blood 1997; 90 (Suppl 1, Part 1 of 2) 256a.